Zepp Health (NYSE:ZEPP – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Profitability
This table compares Zepp Health and Azenta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zepp Health | -15.48% | -15.00% | -6.07% |
| Azenta | -10.34% | 1.43% | 1.19% |
Valuation and Earnings
This table compares Zepp Health and Azenta”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zepp Health | $258.90 million | 0.67 | -$40.07 million | ($2.51) | -4.74 |
| Azenta | $593.82 million | 1.76 | -$55.76 million | ($1.35) | -16.76 |
Zepp Health has higher earnings, but lower revenue than Azenta. Azenta is trading at a lower price-to-earnings ratio than Zepp Health, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Zepp Health has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Azenta has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Zepp Health and Azenta, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zepp Health | 1 | 0 | 1 | 0 | 2.00 |
| Azenta | 1 | 3 | 4 | 0 | 2.38 |
Zepp Health currently has a consensus target price of $64.37, indicating a potential upside of 441.47%. Azenta has a consensus target price of $41.33, indicating a potential upside of 82.65%. Given Zepp Health’s higher probable upside, equities analysts clearly believe Zepp Health is more favorable than Azenta.
Insider and Institutional Ownership
52.6% of Zepp Health shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 36.0% of Zepp Health shares are owned by company insiders. Comparatively, 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Azenta beats Zepp Health on 9 of the 14 factors compared between the two stocks.
About Zepp Health
Zepp Health Corporation operates as a smart wearable and health technology company worldwide. The company operates in two segments: Self-Branded Products and Others, and Xiaomi Wearable Products. It empowers users to live lives by optimizing health, fitness, and wellness journeys through its consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. The company through its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, delivers cloud-based 24/7 actionable insights and guidance to help users attain wellness goals. The company offers smart bands, watches, modules, and scales; and associated accessories, smart hearable products, sportswear, home fitness equipment, home appliances, and smart watch accessories. It also provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. It offers its products under the Amazfit and Zepp brand names in approximately 90 countries. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Zepp Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zepp Health and related companies with MarketBeat.com's FREE daily email newsletter.
